Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Pharma Launches Saladax's MyCare Dosing Assays in China

publication date: Aug 27, 2014
Shanghai Fosun Pharma's diagnostics subsidiary announced the China launch of the MyCare assay tests, which were developed by Saladax Biomedical of the US. The MyCare assays determine optimal chemotherapy dosing based on an individual patient's absorption and clearance rates. In March 2013, Fosun bought $22.4 million of Saladax's D shares, a deal that included China rights to the MyCare assays and gave Fosun majority ownership of Saladax. More details....

Stock Symbols: (SHA: 600196; HK: 02196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital